Summit Day One Agenda

7:00 am Registration

7:55 am Chairs Opening Remarks

The Market Perspective

8:00 am Panel Discussion: Exploring the Dermatology Financing Landscape for 2022 & Beyond


  • What are large pharma looking for when partnering & how can smaller biotechs best prepare to partner
  • How & where do you begin with developing a candidate for the rare disease space
  • Debating how to position your drug candidate in the market where patients have failed other trials

8:30 am Development of a Topical Drug Product in the post-pandemic world

  • Patrick Brunner Associate Professor, Icahn School of Medicine Mount Sinai

9:00 am Growing Our Patient-Focused Dedication to Alopecia Areata

  • Lotus Mallbris Vice President of Global Immunology Development & Medical Affairs, Eli Lilly and Company


  • Reviewing the journey to delivering the world’s first FDA-approved oral JAK inhibitor to demonstrate hair regrowth in Alopecia Areata patients

9:30 am Highlighting Opportunities for Novel Drug Development in Hidradenitis Suppurativa

  • Alexandra Charrow Director Hidradenitis Suppurativa & Neutrophilic Dermatosis Clinic, Brigham & Women’s Hospital


  • Categorizing the disease and providing the context around unmet needs
  • Outlining novel targets and cataloging the promising novel drug candidates for the disease
  • Discussing the need for procedural intervention

10:00 am The Beautiful Collagens of the Skin – Understanding the Extracellular Matrix to Aid Personalized Medicine and Drug Development


  • Different collagens mean very different things
  • The importance of understanding the tissue turnover profiles in Atopic Dermatitis, Hidradenitis Suppurativa and Scleroderma as examples
  • Quantifying collagen age and crosslinks to understand skin health

10:30 am Morning Break & Structured Networking Session

Novel Drug Development & Various Promising Pathways

Track A: IL-4, IL-13 & IL-31 Associated Diseases

Jennifer Gaskin, Senior Director Clinical Operations, Celldex Therapeutics

11:30 am A Novel Approach to Treating Pruritus in Prurigo Nodularis


  • Rationalizing the dual mechanism of action approach as both an antagonist (mu opioid receptor) & agonist (kappa opioid receptor)
  • Providing fresh efficacy data from a phase 3 clinical trial
  • Addressing the challenges with entering the prurigo nodularis market

12:00 pm Spearheading a Novel Compound Targeting the IL-4Ra Cytokine Receptor in Atopic Dermatitis

  • Paul Smith Vice President Discovery Biology, Connect Biopharma


  • Describing the target binding and Th2 cell modulation
  • Clinical responses from a phase 2b clinical trial in atopic dermatitis
  • Future clinical development

12:30 pm Human & Machine: Optimising dermatology clinical trials by AI assisted disease monitoring and quantitative assessment of skin drug effects


  • Standardized high quality skin imaging
  • Smart skin imaging data and image analysis
  • Machine learning and decision support in trials
  • Patient reported outcome and real world evidence

Track B: IL17 Associated Diseases, Alopecia & Vitiligo

John Reader, Chief Scientific Officer, Sareum

11:30 am Spearheading a Novel Drug Candidate in Chronic Inflammatory Skin and Joint Diseases

  • Kristian Reich Founder & Chief Scientific Officer, MoonLake Immunotherapeutics


  • Outlining the emerging story of IL-17A and F in inflammatory diseases
  • How to Optimize targeting an important cytokine pathway – MOA and unique molecule characteristics of the novel IL-17 drug candidate sonelokimab
  • Showcasing disease control by sonelokimab from a phase 2b trial in psoriasis
  • Broadening the spectrum – Preparing for success in HS and PsA

12:00 pm How to Approach Vitiligo: A Holistic Overview of the Vitiligo Drug Development Space

  • John Harris Professor and Chair, Department of Dermatology Founding Director, Vitiligo Clinic and Research Center Founding Director, Autoimmune Therapeutics Institute


  • Benchmarking the most promising novel drug candidates in development for the treatment of Vitiligo
  • Incorporating the perspective from the clinic to enhance drug development
  • Exploring the need for increased DEI in the context of Vitiligo

12:30 pm Presentation brought to you by Quantificare

12:45 pm Early Break

12:50 pm Lunch & Networking

To see more from the agenda, download the full event guide!